BioSpace News Archive

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co.

Viemed Healthcare, Inc. (the “Company” or “Viemed”) (TSX:VMD.TO and NASDAQ:VMD), a home medical equipment supplier that provides post-acute respiratory care services in the United States, announced today that it will host its Quarterly Conference Call on Wednesday, August 5, 2020 at 11:00 a.m. EST.

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced it will release its Q2 2020 financial results after the close on Wednesday, August 12, 2020.

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), today announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2020

Pfizer Inc. and BioNTech SE announced the start of a global Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA candidate from their BNT162 mRNA-based vaccine program, against SARS-CoV-2.

“We are committed to supporting Kodiak as they bring their highly innovative, sight-saving treatment option to patients with vision-threatening retinal diseases. Since 2014, we have been partnering with Kodiak to support the supply of KSI-301 drug substance for use in clinical trials.

Alluma, a nonprofit social enterprise that connects people to essential services through technology and policy expertise, has announced the appointment of three new board members:

This morning, Dr. Paul Bradley, co-founder and Chief Medical Officer of Scripta Insights, partner at BCG Medical Group, and Principal Investigator at Meridian Clinical Research’s internal medicine site in Savannah, Ga., dosed the very first patient in the nation’s first Phase 3 COVID-19 vaccine clinical trial

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching

The first U.S. patients are being dosed today and tomorrow in a Phase 2/3 clinical trial testing whether a messenger RNA (mRNA) vaccine candidate can prevent infection with the virus that causes 2019 coronavirus disease (COVID-19).